Synonyms: BGT 226 | BGT-226 free base | BGT226 | NPV-BGT226
Compound class:
Synthetic organic
Comment: BGT-226 is a novel pan class I PI3K and mTOR inhibitor [1]. The oral formulation of BGT-226 contains its maleate salt (PubChem CID 57336745).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Completed Phase 1/II clinical trial NCT00600275 assessed BGT-226 for advanced solid malignancies, including breast cancer and Cowden syndrome. |